Comment on: Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

Authors

  • Letícia Paula Leonart MSD Brasil, São Paulo, SP, Brazil.
  • Bruno Riveros MSD Brasil, São Paulo, SP, Brazil.
  • Felipe Berlinski MSD Brasil, São Paulo, SP, Brazil.
  • Maria Aparecida Rego MSD Brasil, São Paulo, SP, Brazil.

DOI:

https://doi.org/10.21115/JBES.v14.n3.p267-268

Abstract

Comment on: Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number
needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

Downloads

Download data is not yet available.

Downloads

Published

2022-12-10

How to Cite

Leonart, L. P., Riveros, B., Berlinski, F., & Rego, M. A. (2022). Comment on: Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system. Jornal Brasileiro De Economia Da Saúde, 14(3), 267–268. https://doi.org/10.21115/JBES.v14.n3.p267-268

Issue

Vol. 14 No. 3 (2022)

Section

Artigos